Wall Street analysts expect Fibrocell Science Inc (NASDAQ:FCSC) to announce ($0.31) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Fibrocell Science’s earnings, with the highest EPS estimate coming in at ($0.31) and the lowest estimate coming in at ($0.32). Fibrocell Science reported earnings per share of ($0.42) during the same quarter last year, which would suggest a positive year-over-year growth rate of 26.2%. The company is expected to announce its next quarterly earnings report on Wednesday, August 9th.

According to Zacks, analysts expect that Fibrocell Science will report full-year earnings of ($1.38) per share for the current fiscal year, with EPS estimates ranging from ($1.54) to ($1.23). For the next financial year, analysts forecast that the business will post earnings of ($1.07) per share, with EPS estimates ranging from ($1.17) to ($0.97). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Fibrocell Science.

Fibrocell Science (NASDAQ:FCSC) last announced its quarterly earnings data on Wednesday, May 10th. The company reported ($0.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.29) by $0.29. Fibrocell Science had a negative net margin of 4,307.60% and a negative return on equity of 236.55%.

Several analysts have commented on the stock. HC Wainwright set a $6.00 target price on shares of Fibrocell Science and gave the stock a “buy” rating in a report on Wednesday. ValuEngine upgraded shares of Fibrocell Science from a “sell” rating to a “hold” rating in a report on Thursday, July 20th. Finally, Zacks Investment Research downgraded shares of Fibrocell Science from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th.

An institutional investor recently raised its position in Fibrocell Science stock. Creative Planning increased its stake in Fibrocell Science Inc (NASDAQ:FCSC) by 395.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 61,090 shares of the company’s stock after buying an additional 48,755 shares during the period. Creative Planning owned 0.42% of Fibrocell Science worth $245,000 as of its most recent filing with the SEC. 55.31% of the stock is currently owned by institutional investors.

WARNING: This article was published by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.dailypolitical.com/2017/08/10/0-31-eps-expected-for-fibrocell-science-inc-fcsc-this-quarter.html.

Fibrocell Science (FCSC) opened at 3.18 on Thursday. The company’s 50-day moving average is $3.63 and its 200-day moving average is $2.16. Fibrocell Science has a 12 month low of $0.52 and a 12 month high of $4.64. The stock’s market capitalization is $46.73 million.

Fibrocell Science Company Profile

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Get a free copy of the Zacks research report on Fibrocell Science (FCSC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Fibrocell Science (NASDAQ:FCSC)

Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.